Top

Published in:

01-07-2008 | Epidemiology

Immunohistochemical and molecular subtypes of breast cancer in Nigeria

Authors: Clement A. Adebamowo, Ayotunde Famooto, Temidayo O. Ogundiran, Toyin Aniagwu, Chibuzor Nkwodimmah, Effiong E. Akang

Published in: Breast Cancer Research and Treatment | Issue 1/2008

Abstract

Objective Previous studies suggest that the majority of breast cancer in Africans are hormone receptor negative and thus differ from breast cancer in other populations. We decided to evaluate the hormone receptor status of patients seen in our practice to see if they indeed differ from that of other populations. Methods We prospectively collected and analyzed tumors from consecutive patients presenting to our clinic over an 18 months period from July 2004. During the period, we saw 192 patients without previous histological diagnosis and conducted routine histological and immunohistochemical analysis of their tumors for hormone receptor status. Results Most, 65.1% of tumors were ER+, 54.7% were PR+ and 79.7% were HER2 negative. Majority of the tumors, 77.6% were luminal type A, 2.6% were luminal type B, 15.8% were basal type and the remaining 4.0% (6/152) were HER2+/ER− subtype. We found an association between hormone receptor status and tumor grade but not with stage at presentation. Conclusion We conclude that there is no difference in the pattern of hormone receptors in breast cancer patients of African origin compared to other populations and urge more use of hormone manipulation for management of breast cancer in this population.

Parkin DM, Ferlay J, Hamdi-Cherif M et al (2003) Cancer in Africa: epidemiology and prevention. IARC Press, Lyon

American Cancer Society (2007) Cancer facts & figures 2007. American Cancer Society, Atlanta

Ihekwaba FN (1992) Breast cancer in Nigerian women. Br J Surg 79:771–775PubMedCrossRef

Adebamowo CA, Adekunle OO (1999) Case-controlled study of the epidemiological risk factors for breast cancer in Nigeria. Br J Surg 86:665–668PubMedCrossRef

Anyanwu SN (2000) Breast cancer in eastern Nigeria: a ten year review. West Afr J Med 19:120–125PubMed

Hassan I, Onukak EE, Mabogunje OA (1992) Breast cancer in Zaria, Nigeria. J R Coll Surg Edinb 37:159–161PubMed

Otu AA, Ekanem IO, Khalil MI et al (1989) Characterization of breast cancer subgroups in an African population. Br J Surg 76:182–184PubMedCrossRef

Chiedozi LC (1985) Breast cancer in Nigeria. Cancer 55:653–657PubMedCrossRef

Elmore JG, Moceri VM, Carter D, Larson EB (1998) Breast carcinoma tumor characteristics in black and white women. Cancer 83:2509–2515PubMedCrossRef

10.

Middleton LP, Chen V, Perkins GH et al (2003) Histopathology of breast cancer among African-American women. Cancer 97:253–257PubMedCrossRef

11.

Mbonde MP, Amir H, Mbembati NA et al (1998) Characterisation of benign lesions and carcinomas of the female breast in a sub-Saharan African population. Pathol Res Pract 194:623–629PubMed

12.

Jones BA, Kasi SV, Curnen MG et al (1997) Severe obesity as an explanatory factor for the black/white difference in stage at diagnosis of breast cancer. Am J Epidemiol 146:394–404PubMed

13.

Miller BA, Hankey BF, Thomas TL (2002) Impact of sociodemographic factors, hormone receptor status, and tumor grade on ethnic differences in tumor stage and size for breast cancer in US women. Am J Epidemiol 155:534–545PubMedCrossRef

14.

Gukas ID, Jennings BA, Mandong BM et al (2005) Clinicopathological features and molecular markers of breast cancer in Jos, Nigeria. West Afr J Med 24:209–213PubMed

15.

Ikpatt OF, Kuopio T, Ndoma-Egba R, Collan Y (2002) Breast cancer in Nigeria and Finland: epidemiological, clinical and histological comparison. Anticancer Res 22:3005–3012PubMed

16.

Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502PubMedCrossRef

17.

Burstein HJ (2005) The distinctive nature of Her2 positive breast cancers. N Engl J Med 353:1652–1654PubMedCrossRef

18.

Murray E (2005) Breast cancer clinic at Groote Schuur Hospital. In: AORTIC Newsletter, Edition 2005, pp 10–11

19.

Adebamowo CA, Ogundiran TO, Akang EE, Adams-Campbell LL (2003) ER/PR Status of Nigerian Breast Cancer Patients. In: American Association for Cancer Research Annual Meeting, Edition. AACR, Washington, DC, p 103301

20.

Bertheau P, Cazala-Hatern D, Meignin V et al (1998) Variability of stored immunohistochemical reactivity on stored paraffin slides. J Clin Pathol 51:370–374PubMed

21.

Olapade-Olaopa EO, Mackay HE (1998) Variability of immunohistochemical reactivity on stored paraffin slides. J Clin Pathol 51:943PubMedCrossRef

22.

Goldstein NS, Ferkowicz M, Odish E et al (2003) Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 120:86–92PubMedCrossRef

23.

von Wasielewski R, Mengel M, Nolte M, Werner M (1998) Influence of fixation, antibody clones, and signal amplification on steroid receptor analysis. Breast J 4:22–40CrossRef

24.

Ogbimi RI, Adebamowo CA (2006) Questionnaire survey of working relationships between nurses and doctors in University Teaching Hospitals in Southern Nigeria. BMC Nursing 5:2PubMedCrossRef

25.

Cockburn R, Newton PN, Agyarko EK et al (2005) The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med 2:e100PubMedCrossRef

26.

Mann GB, Fahey VD, Feleppa F, Buchanan MR (2005) Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol 23:5148–5154PubMedCrossRef

27.

Nichols HB, Trentham-Dietz A, Love RR et al (2005) Difference in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women. Cancer Epidemiol Biomarkers Prev 14:41–47PubMedCrossRef

28.

Schechter AL, Stern DF, Vaidyanathan L et al (1984) The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312:513–516PubMedCrossRef

29.

Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182PubMedCrossRef

30.

Clark GM, McGuire WL (1991) Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51:944–948PubMed

31.

Jones BA, Kasl SV, Howe CL et al (2004) African American/white differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer 101:1293–1301PubMedCrossRef

32.

Sørlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874PubMedCrossRef

Title: Immunohistochemical and molecular subtypes of breast cancer in Nigeria
Authors: Clement A. Adebamowo
Ayotunde Famooto
Temidayo O. Ogundiran
Toyin Aniagwu
Chibuzor Nkwodimmah
Effiong E. Akang
Publication date: 01-07-2008
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9694-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified

Intra-hepatic Mitomycin C bolus infusion in the treatment of extensive liver metastases of breast cancer

Prognosis of the upper limb following surgery and radiation for breast cancer

Cancer associated fibroblasts stimulated by transforming growth factor beta1 (TGF-β1) increase invasion rate of tumor cells: a population study

Intermediate to highly suspicious calcification in breast lesions: a radio-pathologic correlation

The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands

Keynote webinar | Spotlight on antibody–drug conjugates in cancer